


**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all previous versions and listings of claims in this application.

**Listing of Claims:**

Claim 1 (currently amended): ~~An immediate release~~ A pharmaceutical tablet formulation suitable for oral immediate release comprising, as an active ingredient, a compound of formula (I):



wherein

~~R¹ is C<sub>1-2</sub> alkyl substituted with one or more fluoro substituents CHF<sub>2</sub>;~~

~~R² is hydrogen, hydroxy, methoxy or ethoxy; and~~

~~n is 0, 1 or 2;~~

~~or a pharmaceutically acceptable salt thereof;~~

~~and at least one a pharmaceutically acceptable diluent or carrier in an amount up to 40% (w/w) of the final formulation selected from the group consisting of monobasic calcium phosphate, dibasic calcium phosphate, tribasic calcium phosphate, lactose, microcrystalline cellulose, silicified microcrystalline cellulose, mannitol, sorbitol, starch, glucose, calcium lactate and calcium carbonate;~~

~~wherein the active ingredient and other optional diluents or excipients make up the composition to 100% w/w.~~

provided that when the active ingredient is other than in the form of a salt, the formulation does not solely contain:

- \* a solution of one active ingredient and water;
- \* a solution of one active ingredient and dimethylsulphoxide; or
  - a solution of one active ingredient in a mixture of ethanol:PEG-660:1,2-hydroxy stearate:water 5:5:90.

Claim 2 (cancelled).

Claim 3 (currently amended): An immediate release A pharmaceutical tablet formulation as claimed in claim 1, wherein the active ingredient is selected from the group consisting of:  
Ph(3-Cl)(5-OCHF<sub>2</sub>)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe);  
Ph(3-Cl)(5-OCHF<sub>2</sub>)-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe);  
Ph(3-Cl)(5-OCH<sub>2</sub>CH<sub>2</sub>F)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe);  
Ph(3-Cl)(5-OCHF<sub>2</sub>)-(R)CH(OH)C(O)-(S)Aze-Pab; and  
Ph(3-Cl)(5-OCHF<sub>2</sub>)-(R)CH(OH)C(O)-(S)Aze-Pab(OH);  
Ph(3-Cl)(5-OCHF<sub>2</sub>)-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF);  
Ph(3-Cl)(5-OCHF<sub>2</sub>)-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OH);  
Ph(3-Cl)(5-OCH<sub>2</sub>CH<sub>2</sub>F)-(R)CH(OH)C(O)-(S)Aze-Pab; or  
Ph(3-Cl)(5-OCH<sub>2</sub>CH<sub>2</sub>F)-(R)CH(OH)C(O)-(S)Aze-Pab(OH).

Claim 4 (withdrawn and currently amended): A pharmaceutical tablet formulation as claimed in claim 1/claim 3, wherein the active ingredient is a crystalline salt of:  
Ph(3-Cl)(5-OCHF<sub>2</sub>)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe);  
Ph(3-Cl)(5-OCHF<sub>2</sub>)-(R)CH(OH)C(O)-(S)Aze-Pab(2,6-diF)(OMe); or  
Ph(3-Cl)(5-OCH<sub>2</sub>CH<sub>2</sub>F)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe).

Claims 5-8 (cancelled).

Claim 9 (withdrawn and currently amended): A method for treating a patient suffering from, or at risk of developing a cardiovascular disorder, comprising administering to the patient a therapeutically effective amount of a pharmaceutical tablet formulation of any one of claims 1 to 83.

Claim 10 (new): A pharmaceutical tablet formulation as claimed in claim 1, wherein the dibasic calcium phosphate is selected from the group consisting of dibasic calcium phosphate dihydrate and dibasic calcium phosphate anhydrate.

Claim 11 (new): A pharmaceutical table formulation as claimed in claim 1, wherein the starch is selected from the group consisting of maize, potato and rice.